[{"id":"b947b4bf-3a48-42a6-9074-c4d0df75bda7","acronym":"NU 15U06","url":"https://clinicaltrials.gov/study/NCT02808143","created_at":"2025-02-25T16:04:51.366Z","updated_at":"2025-02-25T16:04:51.366Z","phase":"Phase 1","brief_title":"Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT02808143 - NU 15U06","lead_sponsor":"Northwestern University","biomarkers":" PD-L1 • PD-1 • PD-L2","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 02/10/2017","start_date":" 02/10/2017","primary_txt":" Primary completion: 05/15/2020","primary_completion_date":" 05/15/2020","study_txt":" Completion: 08/05/2022","study_completion_date":" 08/05/2022","last_update_posted":"2024-06-26"},{"id":"3ba77570-d638-4858-a6b6-8a3dc6dbd96b","acronym":"ALBAN","url":"https://clinicaltrials.gov/study/NCT03799835","created_at":"2021-01-18T18:46:58.727Z","updated_at":"2024-07-02T16:35:26.898Z","phase":"Phase 3","brief_title":"Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients","source_id_and_acronym":"NCT03799835 - ALBAN","lead_sponsor":"UNICANCER","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 516","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2023-12-06"},{"id":"9b29558f-ef64-4f00-9df7-b580538710a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03928275","created_at":"2021-01-18T19:21:28.287Z","updated_at":"2024-07-02T16:35:55.551Z","phase":"Phase 2/3","brief_title":"The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma","source_id_and_acronym":"NCT03928275","lead_sponsor":"Carman Giacomantonio","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • Tice BCG (live attenuated bacillus Calmette-Guerin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 09/01/2022","study_completion_date":" 09/01/2022","last_update_posted":"2023-02-14"},{"id":"76a5ebb5-de98-401a-92f2-affeb4c75df1","acronym":"LUD2002-004","url":"https://clinicaltrials.gov/study/NCT00070070","created_at":"2021-01-18T00:10:32.924Z","updated_at":"2024-07-02T16:36:02.590Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas","source_id_and_acronym":"NCT00070070 - LUD2002-004","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim) • Tice BCG (live attenuated bacillus Calmette-Guerin)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/28/2003","start_date":" 10/28/2003","primary_txt":" Primary completion: 01/03/2006","primary_completion_date":" 01/03/2006","study_txt":" Completion: 09/30/2013","study_completion_date":" 09/30/2013","last_update_posted":"2022-10-12"}]